223 related articles for article (PubMed ID: 12854093)
1. On the analysis of viral load endpoints in HIV vaccine trials.
Hudgens MG; Hoering A; Self SG
Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
[TBL] [Abstract][Full Text] [Related]
2. Use of predictive markers of HIV disease progression in vaccine trials.
Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
[TBL] [Abstract][Full Text] [Related]
3. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
Kim HN; Tabet SR; Corey L; Celum CL
Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
[TBL] [Abstract][Full Text] [Related]
5. Measuring HIV vaccine efficacy.
Hernández-Suárez CM
Stat Med; 2005 Apr; 24(7):983-92. PubMed ID: 15568204
[TBL] [Abstract][Full Text] [Related]
6. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
Mogg R; Mehrotra DV
Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
[TBL] [Abstract][Full Text] [Related]
7. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
[TBL] [Abstract][Full Text] [Related]
9. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
Wick WD
Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
[TBL] [Abstract][Full Text] [Related]
10. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
Mehrotra DV; Li X; Gilbert PB
Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
[TBL] [Abstract][Full Text] [Related]
11. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
[TBL] [Abstract][Full Text] [Related]
12. Remune trial will stop; new trials planned.
James JS
AIDS Treat News; 1999 May; (No 319):1-2. PubMed ID: 11366461
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
[TBL] [Abstract][Full Text] [Related]
14. Chop-lump tests for vaccine trials.
Follmann D; Fay MP; Proschan M
Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
[TBL] [Abstract][Full Text] [Related]
15. Large HIV vaccine trial begins.
Santiago L
GMHC Treat Issues; 1998 Oct; 12(10):1-5. PubMed ID: 11365900
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
17. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
18. [The quest for an HIV vaccine].
Girard MP
Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
[TBL] [Abstract][Full Text] [Related]
19. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
Gilbert PB; Sun Y
Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
[TBL] [Abstract][Full Text] [Related]
20. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
